FDA Approved Products
6,646 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
CYSTEINE HYDROCHLORIDE
cysteine hydrochloride
LOE Approaching
Pfizer
INJECTION · INJECTABLE
1986
NDA30/100
CYSTO-CONRAY
iothalamate meglumine
LOE Approaching
Guerbet
Intravesical, Ureteral · Solution
1972
NDA30/100
CYSTO-CONRAY II
iothalamate meglumine
LOE Approaching
Guerbet
INTRAVESICAL · SOLUTION
1972
NDA30/100
CYSTOGRAFIN
diatrizoate meglumine
LOE Approaching
Bracco
URETHRAL · SOLUTION
1955
NDA30/100
CYSTOGRAFIN DILUTE
diatrizoate meglumine
LOE Approaching
Bracco
URETHRAL · SOLUTION
1955
NDA30/100
CYTADREN
aminoglutethimide
LOE Approaching
Novartis
ORAL · TABLET
1980
NDA30/100
CYTARABINE
cytarabine
LOE Approaching
Entera Bio
INJECTION · INJECTABLE
newly diagnosed therapy-related acute myeloid leukemia (t-AML)AML with myelodysplasia-related changes (AML-MRC) in adults+2
1969
NDA30/100
CYTOMEL
liothyronine sodium
LOE Approaching
Pfizer
ORAL · TABLET
hypothyroidism during the recovery phase of subacute thyroiditis
1956
NDA30/100
CYTOTEC
misoprostol
LOE Approaching
Pfizer
ORAL · TABLET
1988
NDA30/100
CYTOVENE
ganciclovir
LOE Approaching
Roche
ORAL · CAPSULE
cytomegalovirus (CMV) retinitis in immunocompromised adult patientsCMV retinitis in immunocompromised adult patients+2
1994
SMNDA30/100
CYTOVENE
ganciclovir sodium
LOE Approaching
INJECTION · INJECTABLE
cytomegalovirus (CMV) retinitis in immunocompromised adult patientsCMV retinitis in immunocompromised adult patients+2
1989
NDA30/100
CYTOXAN
cyclophosphamide
LOE Approaching
Baxter
INJECTION · INJECTABLE
IV of the Ann Arbor staging system)Hodgkin's disease+13
1959
NDA30/100
CYTOXAN
cyclophosphamide
LOE Approaching
Baxter
ORAL · TABLET
biopsy proven minimal change nephrotic syndrome in pediatric patientslymphoma+2
1959
NDA30/100
CYTOXAN (LYOPHILIZED)
cyclophosphamide
LOE Approaching
Baxter
INJECTION · INJECTABLE
IV of the Ann Arbor staging system)Hodgkin's disease+13
1959
NDA30/100
Carbon Dioxide, USP
carbon dioxide
Growth
INHALATION · GAS
2025
NDA30/100
Carbon Dioxide, USP
carbon dioxide
Growth
INHALATION · GAS
2024
NDA30/100
D.H.E. 45
dihydroergotamine mesylate
LOE Approaching
Bausch + Lomb
INJECTION · INJECTABLE
migraine
1946
NDA30/100
DACOGEN
decitabine
LOE Approaching
Otsuka
INTRAVENOUS · INJECTABLE
untreatedde novo+10
2006
NDA30/100
DALIRESP
roflumilast
LOE Approaching
AstraZeneca
ORAL · TABLET
COPD
2011
NDA30/100
DALMANE
flurazepam hydrochloride
LOE Approaching
Bausch + Lomb
ORAL · CAPSULE
insomnia characterized by difficulty falling asleepfrequent nocturnal awakenings+2
1970
NDA30/100
DANOCRINE
danazol
LOE Approaching
Sanofi
ORAL · CAPSULE
endometriosis amenable to hormonal managementattacks of angioedema of all types (cutaneous+3
1976
NDA30/100
DANTRIUM
dantrolene sodium
LOE Approaching
Pfizer
ORAL · CAPSULE
controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (ethe treatment of skeletal muscle spasm resulting from rheumatic disorders+2
1974
NDA30/100
DANTRIUM
dantrolene sodium
LOE Approaching
Pfizer
INJECTION · INJECTABLE
1979
NDA30/100
DAPIPRAZOLE HYDROCHLORIDE
dapiprazole hydrochloride
LOE Approaching
OPHTHALMIC · SOLUTION/DROPS
1990
NDA30/100